Navigation Links
Martek to Host Investor Conference Call to Discuss Research Presented at the International Conference on Alzheimer's Disease in Vienna, Austria
Date:7/10/2009

COLUMBIA, Md., July 10 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that it will conduct a conference call for investors to discuss DHA research recently presented at the International Conference on Alzheimer's Disease. The call will take place July 13, 2009, at approximately 9 a.m. Eastern Time (ET). All interested parties may listen to the call live via webcast by visiting Martek's web site at http://investors.martek.com.

An archived webcast of the conference call will be available on the Martek's website for thirty days. In addition, a recorded playback of the call will be available for one week and can be accessed by calling 800-633-8284 or 402-977-9140 and entering pass code 214 31512.

Martek Biosciences Corporation is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The Company produces life'sDHA(TM), a sustainable and vegetarian source of DHA omega-3, for use in foods, beverages, infant formula and supplements, and life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in infant formula. For more information on Martek Biosciences, visit http://www.martek.com/.

CONTACT

    Kyle Stults
    Investor Relations
    (410) 740-0081
    investors@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Martek to Present at Upcoming Needham Conference
2. Martek to Announce Second Quarter 2009 Results
3. Martek Announces First Quarter 2009 Financial Results
4. Martek, General Mills Collaborate on Microencapsulation Technology for Food Applications
5. Martek to Present at 11th Annual ICR XChange
6. Martek to Present at Upcoming Needham Conference
7. Martek Announces Fourth Quarter and FY 2008 Financial Results
8. Martek to Announce Fourth Quarter and Fiscal Year 2008 Results
9. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
10. Martek to Present at Upcoming Canaccord Adams Conference
11. Martek to be the Sole Source Supplier of DHA and ARA for Infant Formulas Produced By Grupo Ricap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Texas , Dec. 23, 2014 ... company focused on gynecologic disease, announced today that ... Schuler , Birchview Fund LLC and several Vermillion ... of unregistered shares of Vermillion,s common stock and ... stock in a private placement.  ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... BALTIMORE, June 14, 2011 Arcion Therapeutics , ... therapies for chronic pain, today announced that data from ... of pain associated with painful diabetic neuropathy (PDN) will ... medical meetings.  The first poster will be presented at ...
... PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in Boston, MA.  James Winschel, Sr. Vice President ... PAREXEL at 2:00 p.m. ET on Wednesday, June 22, 2011. ... available through the "Investors" section of PAREXEL,s website ...
... 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today ... the total 240 patients for the Phase IIb ... Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, ... glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 ...
Cached Biology Technology:Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 2Arcion Therapeutics to Present ARC-4558 Phase 2b Data for the Treatment of Pain Associated With Painful Diabetic Neuropathy at Upcoming Medical Meetings 3PAREXEL International to Present at Wells Fargo Healthcare Conference 2Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes 2
(Date:12/22/2014)... 2014  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... Apollo Robbins for the 2015 International CES ... Apollo Robbins will be at the ... demonstrating some of his famous theft techniques to visiting ...
(Date:12/19/2014)... MOUNTAIN VIEW, Calif. , Dec. 18, 2014 /PRNewswire/ ... the publication of a study that pinpoints fine-scale differences ... the United States . Since immigrants ... the United States has served as ... study illuminates how American history and the ongoing mixing ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Columbia have been able to pinpoint more of the ... valuable compounds to the roasting process. Lead author ... the prevailing antioxidants present in dark roasted coffee brew ... high temperatures. Their findings will appear in ...
... Zaragoza (UNIZAR) has studied precipitation trends in Spain,s 10 ... results show that precipitation has declined overall between the ... the rainy season. The rains are heavier in October ... 1946, the average precipitation falling on Spanish hydrological basins ...
... a serious environmental, economic and social problem worldwide as ... ecosystem functions, such as nutrient cycling. Despite substantial research, ... new habitats over native plants that technically should have ... is that these plants are more abundant in introduced ...
Cached Biology News:Roasting coffee beans a dark brown produces valued antioxidants: UBC food scientists 2Rain in Spain is on the decline 2Home and away: How do invasive plant species dominate native species? 2
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
... array sample elements. , , ,Includes: , , ... in PBS (10X): 50 ml , Streptavidin ... 8 packs , 10% Tween-20: 2 x 10 ... x 25 ml , SuperSignal West Pico Stable Peroxide: ...
... polyclonal antibody raised against a ... Immunogen: XAGE2 (NP_570133, ... partial recombinant protein with GST ... Number: NM_130777 ...
...
Biology Products: